NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering
Company: NewBiologix SA Indication: Not Applicable Drug: Recombinant adeno-associated virus (rAAV) vectors Trial Phase: Not Applicable NCT ID: Not Available
Overview
On February 27, 2024, NewBiologix SA, a biotech firm based in Lausanne, Switzerland, announced a strategic partnership with Florabio AS. The collaboration is centered on a licensing agreement that allows NewBiologix to utilize and further develop Florabio's proprietary HEK293 cell line to establish a new platform for the continuous production of rAAV vectors used in gene therapy. This venture aims to improve upon temporary transfection methods with a more stable and scalable approach.
The alliance between the two companies is driven by the common goal of overcoming current limitations in gene therapy manufacturing. By enhancing Florabio's HEK293 suspension cell line—an essential component in gene therapy development—NewBiologix plans to engineer cell clones with superior growth, replication, and transfection capabilities suitable for both research and commercial purposes.
Dr. Igor Fisch, CEO and Co-founder of NewBiologix, emphasizes that their state-of-the-art HEK293 cell line will enable large-scale production of safe and effective vectors, meeting the demand for gene therapy manufacturing on a population level. The modified cell lines are expected to boost productivity and provide uniformity in product quality, purity, and potency.
Florabio, sharing NewBiologix's mission, offers scalable solutions to quicken gene therapy production cost-effectively. In this partnership, Florabio contributes its cutting-edge 'FlorabioHEK293' cell line along with a chemically defined HEK293-specific medium to enhance NewBiologix's endeavors.
NewBiologix is committed to developing an innovative DNA integration platform, combining proprietary bioinformatics tools with comprehensive research and development. The ultimate goal is to support biopharmaceutical companies in rapidly producing and distributing innovative gene therapies at scale.
Moreover, Florabio positions itself as a leader in the production of therapeutic proteins by providing clients with production-ready cell lines, chemically defined culture mediums, and turnkey process solutions, which are all designed with considerations for intellectual property, regulatory compliance, scalability, and robustness. The company’s expertise aims to facilitate a faster and broader reach to the market.